2024-02-11 18:00:00 ET
Summary
- PTC Therapeutics has a diverse portfolio and pipeline of drugs, including a broader DMD treatment.
- The company has not fully expanded its revenue-generating products geographically and is in the process of making the necessary submissions to do so.
- There is some dilution risk from stock compensation plans, but the company already generates revenue to avoid reflexivity risks.
- TAMs are also decent, indicating an interesting story, even if it's all a bit risky for our tastes due to continued cash burn.
Read the full article on Seeking Alpha
For further details see:
PTC Therapeutics: Already Generates Revenues, But Lots Of Outstanding Options